Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Sarcoma 85Lymphoma 58Lymphoma, Large B-Cell, Diffuse 55Lymphoma, Non-Hodgkin 34Osteosarcoma 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 25Hodgkin Disease 25Burkitt Lymphoma 24Testicular Neoplasms 22Neuroectodermal Tumors, Primitive, Peripheral 19Ovarian Neoplasms 18Leukemia 18Lymphoma, Follicular 17Fibrosarcoma 16Testicular Germ Cell Tumor 15Neuroblastoma 15Teratoma 14Rhabdomyosarcoma 14Lymphoma, Large-Cell, Immunoblastic 14Liposarcoma 14Lymphoma, Mantle-Cell 13Lymphoma, Large-Cell, Anaplastic 13Hemangiosarcoma 13Recurrence 12Neurofibrosarcoma 12Leiomyosarcoma 12Histiocytoma, Malignant Fibrous 12Central Nervous System Neoplasms 12Sarcoma, Synovial 11Lymphoma, B-Cell, Marginal Zone 11

Interventions

Rituximab 12Cyclophosphamide 12fludarabine 8dacetuzumab 7blinatumomab 6Tacrolimus 6Busulfan 6Vincristine 5Prednisone 5Etoposide 5Doxorubicin 5Bortezomib 5fludarabine phosphate 4Valganciclovir 4Peripheral Blood Stem Cell Transplantation 4Mycophenolic Acid 4Epoetin Alfa 4venetoclax 3ibrutinib 3Whole-Body Irradiation 3Methotrexate 3Melphalan 3Lenalidomide 3Ganciclovir 3Everolimus 3Dexamethasone 3Darbepoetin alfa 3Alemtuzumab 3tetulomab tetraxetan lu-177 2ponatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Lymphoproliferative Disorders × Ifosfamide × Clear all
NCT02393859 2024-05-29

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

Amgen

Phase 3 Completed
111 enrolled 23 charts 1 FDA
LymphoidOther hematologic neoplasm

Immunoproliferative Disorders, Lymphoproliferative Disorders, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00529503 2015-02-25

A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL

Seagen Inc.

Phase 2 Terminated
151 enrolled
Lymphoid

Hematologic Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡